How do you approach a patient who responded to first line osimertinib but develop an isolated progressing lesion that retains sensitizing EGFR mutation but develops MET amplification?
Would you continue osimertinib after radiation therapy, switch to crizotinib, or consider chemotherapy +/- immunotherapy?
Answer from: Medical Oncologist at Academic Institution
Radiate single site and continue OSI. Repeat liquid biopsy at next progression.
Sign in or Register to read more